CPHI - Wutah pendapatan YoY sajrone 12 wulan kepungkur China Pharma Holdings

China Pharma Holdings (CPHI) is modernizing the synthesis of CNS drugs by implementing automation and bioequivalent developments. The YoY revenue growth rate over the trailing 12-month period confirms this trend, with the current level standing at -11.10. Business stability is driven by demand for generics in China, while localized raw material supply chains completely eliminate logistical risks in drug distribution.
China Pharma Holdings Inc. (CPHI) - rincian metrik lan laporan keuangan

China Pharma Holdings (CPHI) dominance in government generic drug procurement ensures volume inflows, yet China's strict price controls make revenue dynamics a critical marker of business viability. By analyzing year-over-year sales volatility over a rolling 12-month period, investors assess the company's ability to scale market share despite cost inflation, noting that peak growth rates often signal overvalued shares.